Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2022 Earnings Conference Call October 20, 2022 8:30 AM ET Company Participants Shawn Bevec - VP of IR Steve Rusckowski - Chairman, President & Chief Executive Officer Jim Davis - CEO Sam Samad - CFO Conference Call Participants Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Brian Tanquilut - Jefferies A.J. Rice - Credit Suisse Pito Chickering - Deutsche Bank Patrick Donnelly - Citi Operator Welcome to the Quest Diagnostics Third Quarter 2022 Conference Call.

Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q3 2022 Results - Earnings Call Transcript

Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raised its full-year 2022 revenue guidance.

Quest Diagnostics (DGX) Beats on Q3 Earnings, Ups Revenue View

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 8.76% and 5.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) Tops Q3 Earnings and Revenue Estimates

Quest Diagnostics Inc. DGX, -2.25% reported Thursday third-quarter profit and revenue that fell from a year ago but beat expectations, as base business performance rebounding in the latter part of the quarter to help offset inflationary pressure and declining COVID-19 volumes. The health diagnostics information services company's stock was still inactive in the premarket.

Quest Diagnostics earnings fall but beat expectations, even as COVID-19 testing revenue drops 55%

Third quarter revenues of $2.49 billion, down 10.4% from 2021 Third quarter reported diluted earnings per share ("EPS") of $2.17, down 46.0% from 2021; and adjusted diluted EPS of $2.36, down 40.4% from 2021 Third quarter base business revenues of $2.17 billion, up 5.1% from 2021 Full year 2022 reported diluted EPS now expected to be between $8.52 and $8.72; and adjusted diluted EPS expected to be between $9.75 and $9.95 SECAUCUS, N.J. , Oct. 20, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September 30, 2022.

Quest Diagnostics Reports Third Quarter 2022 Financial Results; Raises Guidance for Full Year 2022

Features Nationally Scaled RNA Sequencing and Specimen Collection for Multiple Sclerosis and Non-Alcoholic Fatty Liver Disease with Plans to Expand NASHVILLE, Tenn. , Oct. 18, 2022 /PRNewswire/ -- Decode Health, a healthcare AI company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, today announced a new phase of its collaboration with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to empower drug and diagnostics research and development in the growing fields of metabolic disease and autoimmune neurology.

Decode Health Collaborates with Quest Diagnostics to Speed Biomarker Discovery for Drug and Diagnostics Development

The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.

Quest Diagnostics (DGX) to Report Q3 Earnings: What's in Store?

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Quest Diagnostics (DGX) to Report a Decline in Earnings: What to Look Out for

SECAUCUS, N.J. , Oct. 13, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic testing, unveiled a nationwide campaign, titled "Put Your ___ To The Test.

Quest Encourages Consumers to "Put Your ____ To The Test" in Bold and Disruptive New Ad Campaign

SECAUCUS, N.J. , Oct. 13, 2022 /PRNewswire/ -- Quest Diagnostics  (NYSE: DGX), the world's leading provider of diagnostic information services, today announced Jim Davis, CEO-Elect, has made several organizational changes and leadership appointments of seasoned executives to better support the company's two-point business strategy to accelerate growth and drive operational excellence: Karthik Kuppusamy , Ph.D.

Quest Diagnostics Announces Organizational Changes to Accelerate Growth and Drive Operational Excellence

Analysis of more than 1.1 million test results across the United States suggests more people are living with undiagnosed cancer than before the pandemic, with potential for worse outcomes and higher healthcare costs in the future SECAUCUS, N.J. , Oct. 11, 2022 /PRNewswire/ -- More than two years after the COVID-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation's leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative Quest Diagnostics Health Trends® study by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

Breast and Prostate Cancer Diagnoses Still Lagging During Second Full Year of COVID-19 Pandemic, Quest Diagnostics Health Trends® Study Finds

Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio SECAUCUS, N.J., and AKRON, Ohio , Oct. 5, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Summa Health, a large integrated healthcare delivery system in Ohio, today announced a definitive agreement for Quest to acquire select assets of Summa Health's outreach laboratory services business, referred to as LabCare Plus, in an all-cash transaction.

Quest Diagnostics to Acquire Outreach Lab Services Business of Summa Health

Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.

Quest Diagnostics (DGX) & Peers Progress With Monkeypox Testing

SECAUCUS, N.J. , Sept. 27, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2022 financial results on Thursday, October 20, 2022, before the market opens.

Quest Diagnostics to Release Third Quarter 2022 Financial Results on October 20, 2022

Quest Diagnostics (DGX) inked a new agreement to deliver high-quality diagnostics services for a renowned healthcare provider in Southwest Florida.

Quest Diagnostics (DGX) to Offer Lab Services for Lee Health

Quest Diagnostics has been a pillar in my “Healthy Dividends” portfolio thanks to a safe dividend and long-term growth prospects. Quest has been a key player in the battle against COVID-19 thanks to their ability to handle high testing demand.

Quest Diagnostics: The Market Is Overlooking Long-Term Prospects

Quest Diagnostics Teams Up With Lee Health to Deliver High-Value, Innovative Laboratory Services

SIGA Technologies

One sells a treatment. The other sells a diagnostic test.

Better Monkeypox Stock: SIGA Technologies vs. Quest Diagnostics

TORONTO--(BUSINESS WIRE)-- #EmployeeExperience--Achievers, an industry-leading employee experience software platform, announces its joint win of a Gold award by Brandon Hall Group with its customer case study of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. This win, within the Best Advance in Employee Recognition Program in the Talent Management category, spotlights an organization's workplace strategy and the approach to rewarding and recognizing its workforce to i

Achievers and Quest Diagnostics Win Gold in the 2022 Brandon Hall Group Excellence Technology Awards

Takeda Pharmaceutical

CDPATH supports shared decision-making between patients and healthcare providers; provided at no cost to eligible adult patients who have not yet experienced serious complications* CAMBRIDGE, Mass. , Sept. 14, 2022 /PRNewswire/ -- Takeda ( TSE:4502/NYSE:TAK ) today announced the national launch of the CDPATH™ program, which includes an innovative, validated personalized prognostic tool that uses blood tests† to help predict the potential risk of developing serious Crohn's disease-related complications within three years.1,2 CDPATH is available for use by US-based physicians and offered at no cost to eligible patients††, providing an opportunity for patients to partner with their physicians to map out a personalized disease management plan.

Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease

The Health Care sector sports relative strength during the latest market drop. Quest Diagnostics should see profits fall somewhat as Covid wanes, but there are other upside risks in this low P/E stock.

Quest Diagnostics: Valuation Looks Good As Covid Testing Demand Tapers

SECAUCUS, N.J. , Sept. 8, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley 20th Annual Global Healthcare Conference.

Quest Diagnostics to Speak at the Morgan Stanley 20th Annual Global Healthcare Conference

According to Quest Diagnostics (DGX), this test can differentiate monkeypox viral DNA from other non-variola orthopoxviruses in a specimen, helping to enable a faster final diagnosis.

Quest Diagnostics (DGX) Stock Gains on EUA for Monkeypox Test

First lab-developed test specifically designed to detect Monkeypox virus DNA to receive emergency use authorization during the monkeypox public health emergency SECAUCUS, N.J. , Sept. 7, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the company's lab-developed molecular diagnostic test to aid in the diagnosis of infection with the Monkeypox virus.

FDA Authorizes Quest Diagnostics' Proprietary Monkeypox Test for Emergency Use

Precision medicine innovator uMETHOD now serves Arizona patients in-home; mobile draws in the Greater Phoenix area quadruple in the first month. On-demand remote lab collection supports patients and caregivers across the cognitive decline spectrum, including mild cognitive impairment, mild dementia, and mild Alzheimer's disease.

News for Quest Diagnostics Stock (DGX)